Each tablet contains: Rosuvastatin 10 mg Ezetimibe 10 mg

Turbovas EZ Tablets combine Rosuvastatin, a potent HMG-CoA reductase inhibitor, with Ezetimibe, a cholesterol absorption inhibitor, to provide dual-action lipid-lowering therapy. Rosuvastatin reduces cholesterol synthesis in the liver, while Ezetimibe decreases intestinal cholesterol absorption, resulting in greater reductions in LDL cholesterol than either agent alone. Turbovas EZ Tablets are indicated as an adjunct to diet and lifestyle modifications for comprehensive management of primary hypercholesterolemia and reduction of cardiovascular risk.

Turbovas EZ Tablets are indicated for the treatment of primary hypercholesterolemia as an adjunct to dietary and lifestyle modifications.

Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme involved in cholesterol biosynthesis. By reducing hepatic cholesterol synthesis, it increases hepatic LDL receptor expression and enhances the clearance of circulating low-density lipoprotein (LDL) cholesterol, thereby lowering LDL cholesterol and improving the overall lipid profile. Ezetimibe selectively inhibits the intestinal absorption of cholesterol at the brush border of the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter. This reduces the delivery of intestinal cholesterol to the liver, leading to increased hepatic uptake of LDL cholesterol from the circulation. Together, Rosuvastatin and Ezetimibe provide complementary mechanisms for effective cholesterol reduction.

The recommended dose is one tablet once daily, or as directed by the physician.

Turbovas EZ Tablets are contraindicated in patients with known hypersensitivity to Rosuvastatin, Ezetimibe, or any component of the formulation. They are also contraindicated in patients with active liver disease, including unexplained persistent elevations in hepatic transaminase levels, and in pregnant or breastfeeding women.